TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 (HIV-1))
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 7nMAssay Description:For the Jurkat HIV Latency assay, compounds are dissolved and titrated in DMSO and diluted 100-fold in assay medium (RPMI-1640 containing 10% fetal b...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 (HIV-1))
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 22nMAssay Description:For the Jurkat HIV Latency assay, compounds are dissolved and titrated in DMSO and diluted 100-fold in assay medium (RPMI-1640 containing 10% fetal b...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 (HIV-1))
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 278nMAssay Description:For the Jurkat HIV Latency assay, compounds are dissolved and titrated in DMSO and diluted 100-fold in assay medium (RPMI-1640 containing 10% fetal b...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 (HIV-1))
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 616nMAssay Description:For the Jurkat HIV Latency assay, compounds are dissolved and titrated in DMSO and diluted 100-fold in assay medium (RPMI-1640 containing 10% fetal b...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 (HIV-1))
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 1.05E+3nMAssay Description:For the Jurkat HIV Latency assay, compounds are dissolved and titrated in DMSO and diluted 100-fold in assay medium (RPMI-1640 containing 10% fetal b...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 (HIV-1))
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 1.11E+3nMAssay Description:For the Jurkat HIV Latency assay, compounds are dissolved and titrated in DMSO and diluted 100-fold in assay medium (RPMI-1640 containing 10% fetal b...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 (HIV-1))
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 3.50E+3nMAssay Description:For the Jurkat HIV Latency assay, compounds are dissolved and titrated in DMSO and diluted 100-fold in assay medium (RPMI-1640 containing 10% fetal b...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 (HIV-1))
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 3.68E+3nMAssay Description:For the Jurkat HIV Latency assay, compounds are dissolved and titrated in DMSO and diluted 100-fold in assay medium (RPMI-1640 containing 10% fetal b...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 (HIV-1))
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 4.33E+3nMAssay Description:For the Jurkat HIV Latency assay, compounds are dissolved and titrated in DMSO and diluted 100-fold in assay medium (RPMI-1640 containing 10% fetal b...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 (HIV-1))
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 4.94E+3nMAssay Description:For the Jurkat HIV Latency assay, compounds are dissolved and titrated in DMSO and diluted 100-fold in assay medium (RPMI-1640 containing 10% fetal b...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 (HIV-1))
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 5.17E+3nMAssay Description:For the Jurkat HIV Latency assay, compounds are dissolved and titrated in DMSO and diluted 100-fold in assay medium (RPMI-1640 containing 10% fetal b...More data for this Ligand-Target Pair
TargetGag-Pol polyprotein(Human immunodeficiency virus type 1 (HIV-1))
Glaxosmithkline Intellectual Property Development
US Patent
Glaxosmithkline Intellectual Property Development
US Patent
Affinity DataEC50: 5.00E+4nMAssay Description:For the Jurkat HIV Latency assay, compounds are dissolved and titrated in DMSO and diluted 100-fold in assay medium (RPMI-1640 containing 10% fetal b...More data for this Ligand-Target Pair